Global Anti-Obesity Drugs Market 2015-2019


◆タイトル:Global Anti-Obesity Drugs Market 2015-2019
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:pdf / 英語
Single UserUSD2,500 ⇒換算¥272,500見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥305,200見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD3,500 ⇒換算¥381,500見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



About Obesity
Obesity is a medical condition in which there is surplus accumulation of fat in the body. It is linked with increased illness risk, disability, and death. Although anti-obesity drugs are available in the market, their effectiveness is restricted to maintain weight rather than cure.

TechNavio’s analysts forecast the Global Anti-obesity Drugs market to grow at a CAGR of 39.45 percent over the period 2014-2019.

[Covered in this Report]
The Global Anti-obesity Drugs market can be divided into two segments: Peripherally Acting Anti-obesity Drugs and Centrally Acting Anti-obesity Drugs. This report covers the present scenario and the growth prospects of the Global Anti-obesity Drugs market for the period 2014–2019. To calculate the market size, the report considers the revenue generated from the sales of FDA approved drugs and OTC medications used in the treatment of obesity that are available in the market.
TechNavio’s report, the Global Anti-obesity Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC and EMEA regions; it also covers the Global Anti-obesity Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas

[Key Vendors]
• Arena Pharmaceuticals
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Orexigen Therapeutics
• Vivus

[Other Prominent Vendors]
• Amylin
• Alizyme
• Boehringer Ingelheim
• Eisai
• Merck
• Norgine
• Novo Nordisk
• Pfizer
• Rhythm Pharmaceuticals
• Shionogi USA
• Takeda Pharmaceutical
• Zafgan

[Market Driver]
• Increased Prevalence of Obesity
• For a full, detailed list, view our report

[Market Challenge]
• High Drug Development Costs
• For a full, detailed list, view our report

[Market Trend]
• Stiff Market Competition
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?


01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology


06.Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis

07.Rate of Incidence and Prevalence
07.1.1 US
07.1.2 Europe

08.Types of Obesity
08.1 Monogenic Obesity
08.2 Polygenic Obesity

09.Causes of Obesity
09.1 Unhealthy Eating Habits
09.2 Sedentary Lifestyle
09.3 Certain medications
09.4 Lack of Sleep
09.5 Pregnancy
09.6 Medical problems

10.Classification of Obesity

11.Market Segmentation by Drug Class
11.1 Peripherally Acting Anti-obesity Drugs
11.2 Centrally Acting Anti-obesity Drugs

12.Geographical Segmentation

13.Buying Criteria

14.Market Growth Drivers
14.1 Increase in Prevalence of Obesity
14.2 Increase in Sedentary Lifestyle
14.3 Significant Unmet Needs
14.4 Promising Pipeline and Upcoming Launches of New Drugs

15.Drivers and their Impact

16.Market Challenges
16.1 High Drug Development Costs
16.2 Adverse Side Effects
16.3 Alternative Treatments
16.4 Multiple Drug Recalls

17.Impact of Drivers and Challenges

18.Market Trends
18.1 Fierce Market Competition
18.2 Strict Regulations
18.3 Increase in Strategic Alliances

19.Trends and their Impact

20.Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2013
20.3 Other Prominent Vendors

21.Key Vendor Analysis
21.1 Arena Pharmaceuticals
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Geographical Segmentation
21.1.4 Business Strategy
21.1.5 Recent Developments
21.1.6 SWOT Analysis
21.2 F. Hoffmann-La Roche
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Business Segmentation
21.2.4 Business Segmentation by Revenue 2012 and 2013
21.2.5 Geographical Segmentation by Revenue
21.2.6 Business Strategy
21.2.7 Key Information
21.2.8 SWOT Analysis
21.3 GlaxoSmithKline
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation
21.3.4 Business Segmentation by Revenue 2012 and 2013
21.3.5 Sales by Geography
21.3.6 Pipeline Products
21.3.7 Business Strategy
21.3.8 Key Information
21.3.9 SWOT Analysis
21.4 Orexigen Therapeutics
21.4.1 Business Overview
21.4.2 Business Strategy
21.4.3 Recent Developments
21.4.4 SWOT Analysis
21.5 Vivus
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Business Segmentation by Revenue 2013
21.5.4 Business Segmentation by Revenue 2012 and 2013
21.5.5 Geographical Segmentation by Revenue 2013
21.5.6 Business Strategy
21.5.7 Recent Information
21.5.8 SWOT Analysis

22.Other Reports in this Series

[List of Exhibits]
Exhibit 1: Market Research Methodology
Exhibit 2: Global Anti-obesity Drugs Market 2013-2018 (US$ million)
Exhibit 3: US Prevalence of Adult Overweight and Obesity (NHANES 2011-2012)
Exhibit 4: US Prevalence of Childhood Overweight and Obesity (NHANES 2011-2012)
Exhibit 5: Types of Obesity
Exhibit 6: Causes of Obesity
Exhibit 7: Global Anti-obesity Drugs Market Segmentation by Drug Class
Exhibit 8: Global Anti-obesity Drugs Market by Geographical Segmentation 2014
Exhibit 9: Arena Pharmaceuticals: Geographical Segmentation
Exhibit 10: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
Exhibit 11: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 12: F. Hoffmann-La Roche: Revenue of Pharmaceuticals Division by Geography 2013
Exhibit 13: F. Hoffmann-La Roche: Revenue of Diagnostics Division by Geography 2013
Exhibit 14: GlaxoSmithKline: Business Segmentation 2013
Exhibit 15: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 16: GlaxoSmithKline: Sales by Geography 2013
Exhibit 17: GlaxoSmithKline: Pipeline Products 2013
Exhibit 18: Vivus: Business Segmentation by Revenue 2013
Exhibit 19: Vivus: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 20: Vivus: Geographical Segmentation by Revenue 2013


Arena Pharmaceuticals, F. Hoffmann-La Roche, GlaxoSmithKline, Orexigen Therapeutics, Vivus, Amylin, Alizyme, Boehringer Ingelheim, Eisai, Merck, Norgine, Novo Nordisk, Pfizer, Rhythm Pharmaceuticals, Shionogi USA, Takeda Pharmaceutical, Zafgan





★調査レポート[抗肥満薬の世界市場:末梢作用型抗肥満薬、中枢作用型抗肥満薬] (Global Anti-Obesity Drugs Market 2015-2019 / IRTNTR4645)販売に関する免責事項
[抗肥満薬の世界市場:末梢作用型抗肥満薬、中枢作用型抗肥満薬] (Global Anti-Obesity Drugs Market 2015-2019 / IRTNTR4645)についてEメールでお問い合わせ